US 11,987,626 B2
Treatment of eosinophil or mast cell related disorders
Theresa Marie LaVallee, Rockville, MD (US); and Gerald McMahon, Westport, CT (US)
Assigned to Celldex Therapeutics, Inc., Hampton, NJ (US)
Filed by Celldex Therapeutics, Inc., Hampton, NJ (US)
Filed on Aug. 4, 2020, as Appl. No. 16/984,829.
Application 16/984,829 is a division of application No. 16/270,116, filed on Feb. 7, 2019, granted, now 10,774,146.
Application 16/270,116 is a division of application No. 15/311,949, granted, now 10,239,943, issued on Mar. 26, 2019, previously published as PCT/US2015/032134, filed on May 22, 2015.
Claims priority of provisional application 62/002,395, filed on May 23, 2014.
Claims priority of provisional application 62/162,538, filed on May 15, 2015.
Prior Publication US 2022/0056127 A1, Feb. 24, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 16/24 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)] 7 Claims
 
1. A method of protecting against, treating, or managing an eosinophil related disorder caused by eosinophils in the gastrointestinal tract in response to an allergen, comprising administering to a human subject having the disorder a therapeutically effective amount of a monoclonal antibody which specifically binds to a human KIT receptor comprising SEQ ID NO: 1, or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof each comprises a light chain variable region (“VL”) comprising VL CDRs 1-3 comprising SEQ ID NOs: 2-4, respectively, and a heavy chain variable region (“VH”) comprising VH CDRs 1-3 comprising SEQ ID NOs: 5-7, respectively.